Approval · Notice of Compliance 26990 · 2021
EMGALITY: Notice of Compliance 26990
Issued November 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26990
- Date
- November 4, 2021
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Manufacture process changes
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EMGALITY | Not yet assigned | — |
Medicinal ingredients
- GALCANEZUMAB 120 MG per ML
- GALCANEZUMAB 120 MG per PEN